Salmeterol hydrofluoroalkane inhalation - GlaxoSmithKline

Drug Profile

Salmeterol hydrofluoroalkane inhalation - GlaxoSmithKline

Alternative Names: Salmeterol CFC-free; Salmeterol HFA; Salmeterol HFA inhalation - GlaxoSmithKline; Salmeterol xinafoate HFA; Serevent CFC-free; Serevent Evohaler; Serevent HFA

Latest Information Update: 10 Oct 2011

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 18 Jul 2016 Biomarkers information updated
  • 07 Oct 2011 First generic equivalent available in United Kingdom
  • 02 Dec 2004 No development reported - Phase-III for Asthma in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top